Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 15/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21187325 | 0.82 | PRKDC (0.45) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL21187409 | 0.80 | PDE10A (0.55) | PRKDCKCNH2PDE10A | |
| SCHEMBL21187329 | 0.80 | PRKDC (0.45) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL21177945 | 0.78 | ALDH1A1 (0.43) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21187328 | 0.77 | MAPT (0.44) | PRKDCKCNH2PDE10A | |
| Hydrochloric Acid SCHEMBL29191333 | 0.76 | PRKDC (0.41) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL21178068 | 0.76 | PRKDC (0.45) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21187391 | 0.75 | PRKDC (0.48) | PRKDCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31302322 | 0.74 | PRKDC (0.53) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 | |
| SCHEMBL2419166 | 0.74 | PRKDC (0.53) | PRKDCPIK3CDPIK3CAPIK3CBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | disclosed |
| CN-111757876-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 34/4885PIK3CD 623/4885PIK3CA 271/4885 |
| US-12005127-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 34/4885PIK3CD 623/4885PIK3CA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.